Cholangiocarcinoma
Conditions
Keywords
Cholangiocarcinoma
Brief summary
The main reason for conducting this research is to gain a better understanding of why some people with cholangiocarcinoma are not able to participate in or complete clinical trials. Historically, certain groups of people have been more likely to participate in clinical trials, but there hasn't been much research to understand why this is the case. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. The data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future cholangiocarcinoma patients during clinical trials.
Interventions
None listed
Sponsors
Power Life Sciences Inc.
Study design
Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient is at least 18 years of age * Participant has a diagnosis of Cholangiocarcinoma * Patient has self-identified as planning to enroll in an interventional Cholangiocarcinoma clinical trial * Patient must provide written informed consent
Exclusion criteria
* No diagnosis of Cholangiocarcinoma confirmed * Inability to perform regular electronic reporting * Women who are pregnant, intend to become pregnant, or are lactating * Patient does not understand, sign, and return consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of patients who decide to enroll in a Cholangiocarcinoma Clinical Study. | 3 months |
| Number of Cholangiocarcinoma patients who remain in clinical trial until completion. | 12 months |
Contacts
Primary ContactMichael B Gill
Outcome results
None listed